Konica Minolta Precision Medicine:
Ambry Genetics
Management Presentation
January 2021

CONFIDENTIAL | 1

INTRODUCTIONS
Kiyotaka Fujii
President - Global Healthcare,
Konica Minolta

Aaron Elliott, PhD
CEO, Ambry Genetics

Matthew Silva, PhD
CEO, Invicro

Tom Schoenherr
CCO, Ambry Genetics

 In addition to his role as President –Global Healthcare at Konica Minolta,
Mr. Fujii serves as the Chairman ofAmbry Genetics and Invicro Dr. Elliott joined the Ambry team in2008 in the Research andDevelopment department, working
on development of diagnostic tests.

 Dr. Silva brings 18 years of industry
experience, including 6 years atInvicro Mr. Fujii has previously served as theJapan CEO of SAP, Louis Vuitton,
Cadence Design Systems andQuintiles Transnational During his time at Ambry, Dr. Elliotthas served in several othercapacities, including Director ofGenomic Services, Chief Operating
Officer and Chief Scientific Officer.

 Mr. Schoenherr came to Ambry withmore than 20 years of experience inthe molecular diagnostics space,most recently as the CCO of Omada
Health From 1986 to 1993, Mr. Fujii served
as the first Japanese M&A
investment banker in New York withCredit Suisse First Boston andGoldman Sachs
 Mr. Fujii received an MBA fromHarvard Business School and a B.A.
in Law from the University of Tokyo Dr. Elliott began his career as apostdoctoral fellow at the Novartis
Institute of Functional Genomics
after receiving his PhD in Genetics
from Thomas Jefferson University /The Johns Hopkins University Schoolof Medicine.

 Prior to Invicro, Dr. Silva served as
Senior Director of Translational
Biology at Vertex Pharmaceuticals,
where he ran the imaging andhistopathology groups Previously, Dr. Silva also led groups
at Amgen, Millennium and TakedaPharmaceuticals, focusing on
imaging biomarkers to support drug
discovery and development
 Dr. Silva received his PhD in
Biomedical Engineering fromWorcester Polytechnic Institute Prior to Omada, Mr. Schoenherr
served in similar roles at Counsyl,
Quest Diagnostics, Siemens
Healthcare and Abbot Diagnostics
 Mr. Schoenherr earned his B.S. from
Michigan State University andcompleted the Executive Business
Development Program from theUniversity of Notre Dame

[CONFIDENTIAL] 2

Precision Diagnostics
are the Cornerstone ofPatient

Patient Data

Treatment PlanGenomics

ImagingPathology

Genotype

Phenotype

PRECISION
MEDICINEThe next-generation ofPrecision Medicine is

INTEGRATEDDIAGNOSTICSCONFIDENTIAL | 3

KMPM

Empowering the Future of Healthcare
GenomicClinical Services

Imaging and Pathology
Pharmaceutical Services

Pathology and Technology
Research and Development

PRECISION DIAGNOSTICS / HEALTH INFORMATICS
CLINICAL AND PHARMACEUTICAL DECISION SUPPORTCompany Overview
 Genomics division provides
 Technology leadership
genetic testing and molecular services Market leading in Cancer + Neurology
to evaluate genetic risk for clinical+RNAinsights and Neuro IQ
decision making
 Software and Analytics Platforms
 Imaging Services division provides
iPACS | IA×AI | LATTICE | AVA |imaging and pathology on aBackpack Healthproprietary informatics platform Biomarker research Pathology Services Tissue biomarker
recognized leader in development,and advanced Quanticell technology
deployment and scaled delivery

Key Facts

Financial Summary – Revenue Forecast1ClinicalPharmaCAGR 26%

FY19A

FY20P

FY21P

FY22P

FY23P

FY24P

Growth Initiatives FY2024

GlobalPresence Headquarters in Aliso Viejo, CA Locations in Boston, New Haven, London and Tokyo 8 laboratories including 2 clinics (total of 130,000 sq. ft)
 65,000 sq. ft “super lab” genetic testing facility

Customers

 9,500+ active ordering healthcare providers
 200+ pharma sponsors, including 23 of top 25

TechnicalCapabilities

 Highly scalable capacity
 20 million images under management
 120-person software analysis and bioinformatics team

Employees

 1,300 employees 500+ scientific and technical personnel (100+ PhDs and/or MDs)
 Senior leadership with extensive industry experience1) All financials assume that Ambry, Invicro, KMPMJ and related entities are reorganized into the KMPM entity concurrently with the contemplated transaction.
2) Fiscal years end March of the following calendar year. For example, FY19 ended March 31, 2020.
3) FY20P estimated in Q2

LATTICEJapanExpansion
CoreGrowthCARE
Program

CONFIDENTIAL | 5IMAGING
Biomarker Experts

 Translational biomarker services focused on pathology and radiology, leveraging
Ambry genetic testing Experts in pharmaceutical drug discovery and development and the application
and regulations of integrated biomarkers, from research to clinical trials to CDx
 12+ year history of pharmaceutical services and innovation
Advanced Capabilities

 100+ PhDs and MDs with expertise inlife sciences and technology
 End-to-end solution offering project
management, quality assurance andregulatory compliance Global infrastructure with 8laboratories including 2 clinical imagingcenters
 Expanding qualified partner networkof ~1,800 global centers

Innovative Platform Technology

Trusted Partner

 Proprietary software and analytics
infrastructure combining scientificand medical expertise and cuttingedge informatics and ML/AI
 120-person software analysis andbioinformatics team developing tools
for data management, data scienceand regulatory submission

 200+ Pharma clients: 23 of top 25
 Supporting studies from discovery
research through clinical trials andexpanding into clinical medicine
 2+ new customers per month Record sales in 2020
CONFIDENTIAL | 6

GENOMICS
The Most Trusted Name in Genetic Testing Branded as Ambry Genetics
 20+ year history of innovation, quality &scientific integrity
 +RNAinsight™ technology is the new goldstandard in hereditary cancer genetic testing 1.5M+ tests run
 Market leader among US Genetic Counselors
 #3 share in US oncology, neurology &cardiology markets

First in Innovation

Excellent Payer Positioning 2019: first combined RNA/DNA test:+RNAinsight™
 2017: first paired tumor/ germline Lynch panel 2013: first NGS, BRCA1&2 Post-SCOTUS decision 2012: first NGS hereditary cancer panels 2011: first CLIA/CAP appr. Exome test 2010: first commercial assay using NGS

 In network with 95%+ of health plans 9,500+ active ordering healthcare
providers Premium pricing driven by higher quality(+RNAinsight™)

Next-Generation Laboratory
 Customized testing workflows
 Proprietary LIMS (lab information system)
 Highly scalable capacity
 Highly automated sample processing with50+ Tecan robots
 Dedicated onsite Tecan & Illumina engineers Over 20 Next-Gen Sequencing instruments
including MiSeqs | NextSeqs | HiSeq4000’s |NovaSeqs
 Proprietary sample tracking processincluding tube and plate barcoding as well as
DNA fingerprinting of every sample
CONFIDENTIAL | 7

LARGE ANDGROWING MARKET

Significant Unmet Need
 Global genomics market estimated over ~$40B
 ~800K hereditary cancer tests per year, US 35M+ people meet criteria for testing, USChallenges in the Market$40B~800,000+35,000,000 Identifying the high-risk patients
 Comfortability with genetic testing Population health initiatives
 Lack of genetic counselors both US and GloballyCARE
 Expanding the genomics market
 Identifying individuals at high risk
 Fully automated the genomics process
for patients and clinicians[CONFIDENTIAL] 8

POPULATIONHEALTH PLATFORM
Comprehensive Assessment,
Risk and Education (CARE)IDENTIFICATION

Using Ambry’s Virtual
Assistant (AVA)
High-Risk Screening Tool

PRE-TESTEDUCATION

How genetic testing
can guide early
detection & prevention

GENETIC TESTING
Ordered throughAmbry for qualified
individuals

RESULTS DELIVERY

Test results are delivered
to the ordering provider,and made available to thepatient through AVA

POST-TEST GENETICCOUNSELING

Made available to all
patients who have testing

DOCUMENTATION
Increase quality,
decrease liability

CARE Program Overview
OPPORTUNITY
Millions of high-risk patients unidentified
CARE (Comprehensive Assessment Risk &Education) Fully automated solution | Revenue
generation | Increase quality of patient care

DIFFERENTIATION
Automation of patient identification
Platform can be applied across a health system
to all specialties and disease states

POPULATION HEALTH
CARE for COVID launched 2020
500,000+ patients servedIncremental disease state proof point
CONFIDENTIAL | 9KMPMINTEGRATIONLATTICE Platform

OPPORTUNITY
Global expansion of multi-modal core labCloud Provider – KMPM Clinic and Laboratory Partnership

DIFFERENTIATION
Advanced & validated data management, analytics, interpretation,and reporting across genomic, pathology and imaging
Network of ~1,500 imaging centers and ~300 imaging agent
production facilities, targeting 20+ genomic labs
Best-in-class clinical trial services workflow primed for expansion
and integration with genomics and pathology services
Decentralizing lab via certification of partnered labs and clinics
Centralizing data interpretation and reporting

MOMENTUM
Supply chain, quality, analytic and reporting capabilities
integration plan to collect, standardize and port data
Proof of concept: Lihpao exclusive 3-year agreement to build out
genetic testing in China1) Revenue projection corrected from presentation.

CONFIDENTIAL | 10High RiskImaging Signature

CancerNext

Does NotMeetCriteria

Negative

End

Positive

Meets
Criteria

CancerNext

Improved Cancer Risk
Stratification Using Integrated
Diagnostics in Screening
 More than 50% of BRCA1/2 carriers missed bycurrent NCCN testing criteria
 Digitized mammographic features can help
distinguish BRCA1/2 mutation carriers1,2
 Incorporate image probability score into
hereditary cancer risk modeling for genetic
testing CARE imaging center sites for study andimplementation
 Potential to expand eligible population (>35M)
for hereditary cancer testing

1. Li H, et al. Med Phys 2004, 31:549
2. Gierach et al. Breast Cancer Research 2014, 16:424

CONFIDENTIAL | 11

HIGHLIGHTS
1Konica
Minolta
Precision
Medicine
5

Significant market tailwinds

2

Differentiated technology & services

3

Multiple pillars of growth4

Opportunity to unlock value

Significant value creation opportunity
CONFIDENTIAL | 12

THANK YOU